Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2020-10-27 Earnings Release
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 26, 2020, announcing financial results for the quarter ended September 30, 2020 (Q2 FY21) and half-year ended September 30, 2020 (H1 FY21). It contains key financial highlights such as revenue, EBITDA, PAT, and margin percentages, along with management commentary on performance and outlook. The document is concise (5556 characters) and structured as an initial announcement of quarterly financial results rather than a comprehensive report with detailed financial statements or analysis. There is no indication that this is a full interim or quarterly report (IR), nor is it a detailed management discussion (MDA) or annual report (10-K). The presence of headline financial metrics and growth percentages aligns with the definition of an Earnings Release (ER). H1 2021
2020-10-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an invitation to a Q2 FY21 earnings call for Lasa Supergenerics Ltd. It includes details such as date, time, dial-in numbers, and contact information for the call. There is no financial data or report content, only an announcement of the event. This matches the definition of a Call Transcript (CT) document type, but since this is an invitation and not the transcript itself, it is best classified as a Call Transcript category as it relates directly to the earnings call event. Confidence is high due to clear keywords like 'Earning Call' and detailed call logistics.
2020-10-26 English
Outcome of Board Meeting
Regulatory Filings
2020-10-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, related to dematerialization of securities for the quarter and half year ended September 30, 2020. It is addressed to stock exchanges and confirms compliance with regulatory requirements regarding securities dematerialization and listing. The document is a compliance certificate, not a financial report or detailed filing. It does not contain financial statements or management discussion, nor is it an announcement of voting results or capital changes. It is primarily a regulatory compliance certificate submitted to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS) as a regulatory compliance document that does not fit other specific categories.
2020-10-21 English
Press Release
Legal Proceedings Report Classification · 95% confidence The document is a press release announcing that Lasa Supergenerics Limited has been granted an ex parte interim relief by the Bombay High Court restraining a competitor from selling or dealing in a product using the company's proprietary confidential information. The content focuses on legal proceedings and the impact of the court order on the company's market position and proprietary rights. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full audit report or annual/interim report. It is a legal update related to a court order and litigation. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2020-10-20 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve unaudited financial results for the quarter and half year ended September 30, 2020. It is an intimation to stock exchanges and public about the upcoming board meeting, not the financial results report itself. The document is short (2117 characters) and serves as an announcement rather than containing substantive financial data or analysis. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and board meeting intimation, not an Interim Report (IR) or Earnings Release (ER).
2020-10-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.